Baird raised the firm’s price target on Boston Scientific (BSX) to $120 from $112 and keeps an Outperform rating on the shares. The firm called it a top idea with 2025 shaping up to be another year of best-in-class-growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $117 from $101 at Canaccord
- Boston Scientific price target raised to $122 from $107 at Citi
- Boston Scientific Reports Strong 2024 Financial Growth
- Boston Scientific Shines with Strong Earnings Performance
- Boston Scientific price target raised to $115 from $110 at BofA